New magnetic resonance imaging biomarkers for the diagnosis of multiple sclerosis

Expert Opinion on Medical Diagnostics

Volumn 6, Issue 2, 2012, Pages 109-120

  Filippi, Massimo ^a   Rocca, Maria A ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Biomarkers; Clinically isolated syndrome; Conventional MRI; Diagnosis; Diffusion tensor MRI; Functional MRI; Magnetization transfer MRI; Multiple sclerosis; Prognosis; Proton MR spectroscopy

Indexed keywords

BRAIN ATROPHY; BRAIN CORTEX; CEREBROSPINAL FLUID; DIAGNOSTIC ACCURACY; DISEASE MARKER; GRAY MATTER; HUMAN; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; RADIODIAGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SPINAL CORD;

EID: 84858046924     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2012.657624     Document Type: Review

References (85)

1. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6
2. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-17
3. Simon JH, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: consortium of MS centers consensus guidelines. AJNR Am J Neuroradiol 2006;27:455-61
4. Lovblad KO, Anzalone N, Dorfler A, et al. MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol 2010;31:983-9
5. Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008;7:615-25
6. Giorgio A, Battaglini M, Smith SM, et al. Brain atrophy assessment in multiple sclerosis: importance and limitations. Neuroimaging Clin N Am 2008;18:675-86; xi
7. Ropele S, Fazekas F. Magnetization transfer MR imaging in multiple sclerosis. Neuroimaging Clin N Am 2009;19:27-36
8. Rovaris M, Agosta F, Pagani E, et al. Diffusion tensor MR imaging. Neuroimaging Clin N Am 2009;19:37-43
9. Sajja BR, Wolinsky JS, Narayana PA. Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 2009;19:45-58
10. Filippi M, Rocca MA. Functional MR imaging in multiple sclerosis. Neuroimaging Clin N Am 2009;19:59-70
11. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95
12. Ormerod IE, Miller DH, McDonald WI, et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain 1987;110(Pt 6):1579-616
13. Filippi M, Gawne-Cain ML, Gasperini C, et al. Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology 1998;50:238-44
14. Barkhof F, Filippi M, van Waesberghe JH, et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology 1997;49:1682-8
15. Lycklama G, Thompson A, Filippi M, et al. Spinal-cord MRI in multiple sclerosis. Lancet Neurol 2003;2:555-62
16. Miller DH, Newton MR, van der Poel JC, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology 1988;38:175-9
17. Davies MB, Williams R, Haq N, et al. MRI of optic nerve and postchiasmal visual pathways and visual evoked potentials in secondary progressive multiple sclerosis. Neuroradiology 1998;40:765-70
18. Rocca MA, Hickman SJ, Bo L, et al. Imaging the optic nerve in multiple sclerosis. Mult Scler 2005;11:537-41
19. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
20. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120(Pt 11):2059-69
21. Tintore M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000;21:702-6
22. Tintore M, Rovira A, Rio J, et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003;60:27-30
23. Swanton JK, Fernando K, Dalton CM, et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006;77:830-3
24. Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007;6:677-86
25. Rovira A, Swanton J, Tintore M, et al. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol 2009;66:587-92
26. Montalban X, Tintore M, Swanton J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010;74:427-34
27. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302
28. Charil A, Yousry TA, Rovaris M, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol 2006;5:841-52
29. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-74
30. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9
31. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635-41
32. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-64
33. Minneboo A, Barkhof F, Polman CH, et al. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol 2004;61:217-21
34. Rocca MA, Agosta F, Sormani MP, et al. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol 2008;255:683-91
35. Tintore M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968-72
36. Swanton JK, Fernando KT, Dalton CM, et al. Early MRI in optic neuritis: the risk for disability. Neurology 2009;72:542-50
37. Summers M, Fisniku L, Anderson V, et al. Cognitive impairment in relapsing-remitting multiple sclerosis can be predicted by imaging performed several years earlier. Mult Scler 2008;14:197-204
38. Lucchinetti CF, Popescu BFG, Bunyan RF, et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011;365:2188-97
39. Geurts JJ, Pouwels PJ, Uitdehaag BM, et al. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005;236:254-60
40. Calabrese M, De Stefano N, Atzori M, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 2007;64:1416-22
41. Filippi M, Rocca MA, Calabrese M, et al. Intracortical lesions: relevance for new MRI diagnostic criteria for multiple sclerosis. Neurology 2010;75:1988-94
42. Fernando KT, Tozer DJ, Miszkiel KA, et al. Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2005;128:2911-25
43. Iannucci G, Tortorella C, Rovaris M, et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol 2000;21:1034-8
44. Ranjeva JP, Audoin B, Au Duong MV, et al. Local tissue damage assessed with statistical mapping analysis of brain magnetization transfer ratio: relationship with functional status of patients in the earliest stage of multiple sclerosis. AJNR Am J Neuroradiol 2005;26:119-27
45. Gallo A, Rovaris M, Benedetti B, et al. A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis. J Neurol 2007;254:78-83
46. Gallo A, Rovaris M, Riva R, et al. Diffusion-tensor magnetic resonance imaging detects normal-appearing white matter damage unrelated to short-term disease activity in patients at the earliest clinical stage of multiple sclerosis. Arch Neurol 2005;62:803-8
47. Raz E, Cercignani M, Sbardella E, et al. Clinically isolated syndrome suggestive of multiple sclerosis: voxelwise regional investigation of white and gray matter. Radiology 2010;254:227-34
48. Pagani E, Filippi M, Rocca MA, et al. A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage 2005;26:258-65
49. Ciccarelli O, Toosy AT, Hickman SJ, et al. Optic radiation changes after optic neuritis detected by tractography-based group mapping. Hum Brain Mapp 2005;25:308-16
50. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433-7
51. Rovaris M, Gallo A, Falini A, et al. Axonal injury and overall tissue loss are not related in primary progressive multiple sclerosis. Arch Neurol 2005;62:898-902
52. Pulizzi A, Rovaris M, Judica E, et al. Determinants of disability in multiple sclerosis at various disease stages: a multiparametric magnetic resonance study. Arch Neurol 2007;64:1163-8
53. Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2004;127:1361-9
54. Kapeller P, Brex PA, Chard D, et al. Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis. Mult Scler 2002;8:207-10
55. Wattjes MP, Harzheim M, Lutterbey GG, et al. Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis. Neuroradiology 2008;50:123-9
56. Audoin B, Ranjeva JP, Au Duong MV, et al. Voxel-based analysis of MTR images: a method to locate gray matter abnormalities in patients at the earliest stage of multiple sclerosis. J Magn Reson Imaging 2004;20:765-71
57. Khalil M, Enzinger C, Langkammer C, et al. Cognitive impairment in relation to MRI metrics in patients with clinically isolated syndrome. Mult Scler 2011;17:173-80
58. Audoin B, Fernando KT, Swanton JK, et al. Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. Brain 2006;129:1031-9
59. Rovaris M, Judica E, Ceccarelli A, et al. A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS. J Neurol 2008;255:1209-14
60. Ceccarelli A, Filippi M, Neema M, et al. T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Mult Scler 2009;15:678-86
61. Brex PA, Jenkins R, Fox NC, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000;54:1689-91
62. Dalton CM, Brex PA, Jenkins R, et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;73:141-7
63. Dalton CM, Chard DT, Davies GR, et al. Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. Brain 2004;127:1101-7
64. Ceccarelli A, Rocca MA, Pagani E, et al. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage 2008;42:315-22
65. Henry RG, Shieh M, Okuda DT, et al. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79:1236-44
66. Raz E, Cercignani M, Sbardella E, et al. Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. Radiology 2010;257:448-54
67. Rocca MA, Mezzapesa DM, Falini A, et al. Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage 2003;18:847-55
68. Filippi M, Rocca MA, Mezzapesa DM, et al. Simple and complex movement-associated functional MRI changes in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis. Hum Brain Mapp 2004;21:108-17
69. Audoin B, Ibarrola D, Ranjeva JP, et al. Compensatory cortical activation observed by fMRI during a cognitive task at the earliest stage of MS. Hum Brain Mapp 2003;20:51-8
70. Forn C, Rocca M, Valsasina P, et al. Functional magnetic resonance imaging correlates of cognitive performance in patients with a clinically isolated syndrome suggestive of multiple sclerosis at presentation: anactivation and connectivity study. Mult Scler 2011; DOI: 10.1177/1352458511417744
71. Rocca MA, Mezzapesa DM, Ghezzi A, et al. A widespread pattern of cortical activations in patients at presentation with clinically isolated symptoms is associated with evolution to definite multiple sclerosis. AJNR Am J Neuroradiol 2005;26:1136-9
72. Audoin B, Reuter F, Duong MV, et al. Efficiency of cognitive control recruitment in the very early stage of multiple sclerosis: a one-year fMRI follow-up study. Mult Scler 2008;14:786-92
73. Sicotte NL, Voskuhl RR, Bouvier S, et al. Comparison of multiple sclerosis esions at 1.5 and 3.0 Tesla. Invest Radiol 2003;38:423-7
74. Wattjes MP, Lutterbey GG, Harzheim M, et al. Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol 2006;16:2067-73
75. Wattjes MP, Lutterbey GG, Gieseke J, et al. Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol 2007;28:54-9
76. Wattjes MP, Harzheim M, Lutterbey GG, et al. Does high field MRI allow an earlier diagnosis of multiple sclerosis? J Neurol 2008;255:1159-63
77. Hammond KE, Metcalf M, Carvajal L, et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64:707-13
78. Mainero C, Benner T, Radding A, et al. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology 2009;73:941-8
79. Kangarlu A, Bourekas EC, Ray-Chaudhury A, et al. Cerebral cortical lesions in multiple sclerosis detected by MR imaging at 8 Tesla. AJNR Am J Neuroradiol 2007;28:262-6
80. Kollia K, Maderwald S, Putzki N, et al. First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5T and 7T. AJNR Am J Neuroradiol 2009;30:699-702
81. Cohen-Adad J, Benner T, Greve D, et al. In vivo evidence of disseminated subpial T2.. *signal changes in multiple sclerosis at 7 T: a surface-based analysis. Neuroimage 2011;57:55-62
82. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-85
83. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82
84. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11
85. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97